Journal article
Declining efficacy of moxifloxacin for Mycoplasma genitalium infection: time for fluoroquinolone-resistance guided therapy?
Laura G Matthews, Lenka A Vodstrcil, Natasha L Wild, Erica L Plummer, Ivette Aguirre, Kay Htaik, Gerald L Murray, Vesna De Petra, Michelle Sait, Norelle Sherry, Catriona S Bradshaw
J Infect Dis | Published : 2026
Open access
Abstract
BACKGROUND: We assessed trends in moxifloxacin-use and efficacy for MG over a decade at Melbourne Sexual Health Centre (MSHC). Specific Mycoplasma genitalium (MG) mutations, namely ParC-S83I, have been associated with moxifloxacin failure. In 2024 MSHC introduced ParC-S83 testing, recommending moxifloxacin for ParC-S83 wildtype infections and alternative regimens if the ParC-S83I mutation was detected. We present preliminary impacts of ParC-S83 testing on moxifloxacin-use and efficacy. METHODS: Clients with MG from 2015-2024 were treated with doxycycline preceding macrolide-resistance guided azithromycin or moxifloxacin. Clients with a test-of-cure 14-90 days after completing moxifloxacin wh..
View full abstractRelated Projects (1)
Grants
Awarded by National Health and Medical Research Council
Awarded by Australian Research Council Industrial Research Translation Hub